<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05002595</url>
  </required_header>
  <id_info>
    <org_study_id>SCH-HP-2021</org_study_id>
    <nct_id>NCT05002595</nct_id>
  </id_info>
  <brief_title>H. Pylori Treatment Between Modified Quadruple Regimen and Tailored Therapy</brief_title>
  <official_title>Comparison of Helicobacter Pylori Treatment Between Modified Quadruple Therapy and Tailored Eradication Based on the Presence of Clarithromycin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soonchunhyang University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Soonchunhyang University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rate of H. pylori resistance to antimicrobial agents including clarithromycin (CAM) has&#xD;
      increased worldwide. Eradication failure using triple therapy is strongly associated with&#xD;
      CAM-resistant H. pylori. The tailored therapy is defined as a targeted H. pylori eradication&#xD;
      which emphasizes on predicting individual drug responses before treatment.&#xD;
&#xD;
      Dual priming oligonucleotide (DPO)-based multiplex polymerase chain reaction (PCR) was&#xD;
      developed to diagnose H. pylori infection and identify CAM resistance. The use of DPO-PCR has&#xD;
      increased the tailored H. pylori eradication rate in Korea. If DPO-PCR testing is not&#xD;
      available, a 14-day modified bismuth-containing quadruple regimen is recommended as a&#xD;
      first-line H. pylori eradication. However, there is no comparison study between modified&#xD;
      quadruple therapy and tailored eradication based on the presence of CAM resistance using&#xD;
      DPO-PCR.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators aim to evaluate the success rate, adverse drug events, and&#xD;
      cost-effectiveness of modified quadruple therapy, compared with tailored eradication based on&#xD;
      the presence of CAM resistance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">August 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>H. pylori infection status</measure>
    <time_frame>6 weeks</time_frame>
    <description>Rate of successful H. pylori eradication</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">270</enrollment>
  <condition>H. Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Modified quadruple therapy</arm_group_label>
    <description>pantoprazole 40mg bid, amoxicillin 1000mg bid, metronidazole 750mg bid, bismuth subcitrate 600mg bid for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tailored eradication</arm_group_label>
    <description>pantoprazole 40mg bid, amoxicillin 1000mg bid, clarithromycin 500mg bid or pantoprazole 40mg bid, tetracycline 1000mg bid, metronidazole 750mg bid, bismuth subcitrate 600mg bid for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>H. pylori eradication</intervention_name>
    <description>Antimicrobial agents for H. pylori eradication</description>
    <arm_group_label>Modified quadruple therapy</arm_group_label>
    <arm_group_label>Tailored eradication</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biospecimen would be obtained for urease test (commercial name: CLOtest) or molecular test&#xD;
      (DPO-PCR).&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        H. pylori-infected patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gastroscopy can be performed&#xD;
&#xD;
          -  H. pylori test and pathological analysis can be performed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 20 or &gt; 80 years&#xD;
&#xD;
          -  Anemia (serum hemoglobin level &lt; 10 g/dL)&#xD;
&#xD;
          -  Severe systemic disease&#xD;
&#xD;
          -  Advanced chronic liver disease&#xD;
&#xD;
          -  Use of certain medications, including proton pump inhibitors, H2- receptor&#xD;
             antagonists, or antibiotics&#xD;
&#xD;
          -  History of H. pylori eradication&#xD;
&#xD;
          -  History of gastric surgery&#xD;
&#xD;
          -  Recent history of upper gastrointestinal bleeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun-Hyung Cho, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Soonchunhyang University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Digestive Disease Center, Soonchunhyang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>04401</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 4, 2021</study_first_submitted>
  <study_first_submitted_qc>August 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Soonchunhyang University Hospital</investigator_affiliation>
    <investigator_full_name>Jun-Hyung Cho</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

